Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
Loading...
Access rights
openAccess
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
Date
2017-02-01
Department
Major/Subject
Mcode
Degree programme
Language
en
Pages
11
Series
Nanomedicine: Nanotechnology, Biology and Medicine, Volume 13, issue 2, pp. 515-525
Abstract
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.Description
Keywords
Glycosaminoglycans, Malaria, Nanomedicine, Plasmodium, Targeted drug delivery
Other note
Citation
Marques, J, Valle-Delgado, J J, Urbán, P, Baró, E, Prohens, R, Mayor, A, Cisteró, P, Delves, M, Sinden, R E, Grandfils, C, de Paz, J L, García-Salcedo, J A & Fernàndez-Busquets, X 2017, ' Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery ', Nanomedicine: Nanotechnology, Biology and Medicine, vol. 13, no. 2, pp. 515-525 . https://doi.org/10.1016/j.nano.2016.09.010